PT  - JOURNAL ARTICLE
AU  - Dami Collier
AU  - Sonny M. Assennato
AU  - Ben Warne
AU  - Nyarie Sithole
AU  - Katherine Sharrocks
AU  - Allyson Ritchie
AU  - Pooja Ravji
AU  - Matthew Routledge
AU  - Dominic Sparkes
AU  - Jordan Skittrall
AU  - Anna Smielewska
AU  - Isobel Ramsey
AU  - Neha Goel
AU  - Martin Curran
AU  - David Enoch
AU  - Rhys Tassell
AU  - Michelle Lineham
AU  - Devan Vaghela
AU  - Clare Leong
AU  - Hoi Ping Mok
AU  - John Bradley
AU  - Kenneth GC Smith
AU  - Vivienne Mendoza
AU  - Nikos Demiris
AU  - Martin Besser
AU  - Gordon Dougan
AU  - Paul J. Lehner
AU  - Mark J. Siedner
AU  - Hongyi Zhang
AU  - Claire S. Waddington
AU  - Helen Lee
AU  - Ravindra K. Gupta
AU  - and the CITIID-NIHR COVID BioResource Collaboration
TI  - Dramatic impact of rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical validation trial and implementation study
AID  - 10.1101/2020.05.31.20114520
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.31.20114520
4099  - http://medrxiv.org/content/early/2020/06/11/2020.05.31.20114520.short
4100  - http://medrxiv.org/content/early/2020/06/11/2020.05.31.20114520.full
AB  - Background There is urgent need for safe and efficient triage protocols for hospitalized COVID-19 suspects to appropriate isolation wards. A major barrier to timely discharge of patients from the emergency room and hospital is the turnaround time for many SARS-CoV-2 nucleic acid tests. We validated a point of care nucleic acid amplification based platform SAMBA II for diagnosis of COVID-19 and performed an implementation study to assess its impact on patient disposition at a major academic hospital.Methods We prospectively recruited COVID-19 suspects admitted to hospital (NCT04326387). In an initial pilot phase, individuals were tested using a nasal/throat swab with the SAMBA II SARS-CoV-2 rapid diagnostic platform in parallel with a combined nasal/throat swab for standard central laboratory RT-PCR testing. In the second implementation phase, we examined the utility of adding the SAMBA platform to routine care. In the pilot phase, we measured concordance and assay validity using the central laboratory as the reference standard and assessed assay turnaround time. In the implementation phase, we assessed 1) time to definitive bed placement from admission, 2) time spent on COVID-19 holding wards, 3) proportion of patients in isolation versus COVID negative areas following a test, comparing the implementation phase with the 10 days prior to implementation.Results In phase I, 149 participants were included in the pilot. By central laboratory RT-PCR testing, 32 (21.5%) tested positive and 117 (78.5%). Sensitivity and specificity of the SAMBA assay compared to RT-PCR lab test were 96.9% (95% CI 0.838-0.999) and 99.1% (0.953-0.999), respectively. Median time to result was 2.6 hours (IQR 2.3 to 4.8) for SAMBA II SARS-CoV-2 test and 26.4 hours (IQR 21.4 to 31.4) for the standard lab RT-PCR test (p<0.001). In the first 10 days of the SAMBA implementation phase, we conducted 992 tests, with the majority (59.8%) used for hospital admission, and the remainder for pre-operative screening (11.3%), discharge planning (10%), in-hospital screening of new symptoms (9.7%). Comparing the pre-implementation (n=599) with the implementation phase, median time to definitive bed placement from admission was reduced from 23.4 hours (8.6-41.9) to 17.1 hours (9.0-28.8), P=0.02 in Cox analysis, adjusted for age, sex, comorbidities and clinical severity at presentation. Mean length of stay on a COVID-19 ‘holding’ ward decreased from 58.5 hours to 29.9 hours (P<0.001). Use of single occupancy rooms amongst those tested fell from 30.8% before to 21.2% (P=0.03) and 11 hospital bay closures (on average 6 beds each) were avoided after implementation of the POC assay.Conclusions The SAMBA II SARS-CoV-2 rapid assay performed well compared to a centralized laboratory RT-PCR platform and demonstrated shorter time to result both in trial and real-world settings. It was also associated with faster time to definitive bed placement from the emergency room, greater availability of isolation rooms, avoidance of hospital bay closures, and greater movement of patients to COVID negative open “green” category wards. Rapid testing in hospitals has the potential to transform ability to deal with the COVID-19 epidemic.Competing Interest StatementThis work was supported by the Wellcome Trust (Senior Research Fellowship to RKG WT108082AIA and PhD Research Fellowship to DAC; Principal Research Fellowship 210688/Z/18/Z to PJL), Addenbrookes Charitable Trust to PJL, National Institute of Health Research (NIHR) Cambridge BRC Clinical TrialNCT04326387Funding StatementThis work was supported by the Wellcome Trust (Senior Research Fellowship to RKG WT108082AIA and PhD Research Fellowship to DAC; Principal Research Fellowship 210688/Z/18/Z to PJL), Addenbrookes Charitable Trust to PJL, National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the East of England - Essex Research Ethics Committee. HRA and Health and Care Research Wales (HCRW) approval was received.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata can be obtained from the corresponding author by email at rkg20{at}cam.ac.uk